These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 30824788

  • 1. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
    Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, Liew D.
    Sci Rep; 2019 Mar 01; 9(1):3256. PubMed ID: 30824788
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.
    Clin Drug Investig; 2016 Aug 01; 36(8):649-59. PubMed ID: 27221806
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, Ji L.
    J Med Econ; 2019 Apr 01; 22(4):336-343. PubMed ID: 30663458
    [Abstract] [Full Text] [Related]

  • 4. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    Diabet Med; 2015 Jul 01; 32(7):890-8. PubMed ID: 25817050
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P.
    Prim Care Diabetes; 2015 Feb 01; 9(1):39-47. PubMed ID: 24840612
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    BMC Health Serv Res; 2015 Nov 05; 15():496. PubMed ID: 26541516
    [Abstract] [Full Text] [Related]

  • 7. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
    Abushanab D, Liew D, Marquina C, Al-Badriyeh D, Ademi Z.
    Endocr Pract; 2022 Jan 05; 28(1):16-24. PubMed ID: 34389513
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
    Parizo JT, Goldhaber-Fiebert JD, Salomon JA, Khush KK, Spertus JA, Heidenreich PA, Sandhu AT.
    JAMA Cardiol; 2021 Aug 01; 6(8):926-935. PubMed ID: 34037681
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L.
    Curr Med Res Opin; 2017 Feb 01; 33(2):359-369. PubMed ID: 27817216
    [Abstract] [Full Text] [Related]

  • 10. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
    Elsisi GH, Anwar MM, Khattab M, Elebrashy I, Wafa A, Elhadad H, Awad M, Carapinha JL.
    J Med Econ; 2020 Aug 01; 23(8):908-914. PubMed ID: 32364032
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
    Abad Paniagua EJ, Casado Escribano P, Fernández Rodriguez JM, Morales Escobar FJ, Betegón Nicolás L, Sánchez-Covisa J, Brosa M.
    Aten Primaria; 2015 Oct 01; 47(8):505-13. PubMed ID: 25555492
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
    Van der Linden N, Van Olst S, Nekeman S, Uyl-de Groot CA.
    Diabet Med; 2021 Apr 01; 38(4):e14371. PubMed ID: 32745279
    [Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M.
    Clin Drug Investig; 2014 Feb 01; 34(2):135-46. PubMed ID: 24243529
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.